CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
CARsgen Therapeutics Holdings Ltd. has announced positive interim results, highlighting significant progress in their CAR T-cell therapies, particularly zevorcabtagene autoleucel, approved for multiple myeloma treatment in China, and achieving insurance coverage in 20 provinces. They’ve completed patient enrollment for a Phase II trial of satricabtagene autoleucel for gastric cancers and have ongoing preclinical collaborations with Moderna. The company also reported advancements with their proprietary CARcelerate platform, which may produce more potent CAR T cells with a reduced manufacturing time.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.
